Q32 Bio and Homology Medicines Announce Merger Agreement

Provided By PR Newswire

Last update: Nov 16, 2023

--The combined company will operate as Q32 Bio Inc., advancing the development of Q32 Bio's two clinical development candidates, bempikibart (ADX-914) in Phase 2 for the treatment of atopic dermatitis (AD) and alopecia areata (AA), and ADX-097 entering Phase 2 for the treatment of complement disorders--